{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T17:15:15Z","timestamp":1765041315042,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00380-022-02151-7","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T13:25:57Z","timestamp":1659101157000},"page":"171-176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of lipoprotein(a) levels on primary patency after endovascular therapy for femoropopliteal lesions"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6778-751X","authenticated-orcid":false,"given":"Koji","family":"Yanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokuni","family":"Akahori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Imanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojiro","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagataka","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takamasa","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"key":"2151_CR1","doi-asserted-by":"publisher","first-page":"4582","DOI":"10.1016\/S0021-9258(18)32663-2","volume":"258","author":"JW Gaubatz","year":"1983","unstructured":"Gaubatz JW, Heideman C, Gotto AM, Morrisett JD, Dahlen GH (1983) Human plasma lipoprotein(a). Struct Prop J Biol Chem 258:4582\u20134589","journal-title":"Struct Prop J Biol Chem"},{"key":"2151_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0021-9150(90)90177-K","volume":"85","author":"AD Mbewu","year":"1990","unstructured":"Mbewu AD, Durrington PN (1990) Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis 85:1\u201314","journal-title":"Atherosclerosis"},{"key":"2151_CR3","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1161\/01.ATV.15.9.1492","volume":"15","author":"LB Nielsen","year":"1995","unstructured":"Nielsen LB, Nordestgaard BG, Stender S, Niendorf A, Kjeldsen K (1995) Transfer of lipoprotein(a) and LDL into aortic intima in normal and in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 15:1492\u20131502","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2151_CR4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/330132a0","volume":"330","author":"JW McLean","year":"1987","unstructured":"McLean JW, Tomlinson JE, Kuang W, Eaton DL, Chen EY, Lawn RM (1987) cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330:132\u2013137","journal-title":"Nature"},{"key":"2151_CR5","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1161\/01.CIR.102.10.1082","volume":"102","author":"J Danesh","year":"2000","unstructured":"Danesh J, Collins R, Peto R (2000) Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies. Circulation 102:1082\u20131085","journal-title":"Circulation"},{"key":"2151_CR6","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1161\/ATVBAHA.112.255521","volume":"32","author":"D Gurdasani","year":"2012","unstructured":"Gurdasani D, Sjouke B, Tsimikas S, Hovingh GK, Luben RN, Wainwright NW, Pomilla C, Wareham NJ, Khaw KT, Boekholdt SM, Sandhu MS (2012) Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol 32:3058\u20133065","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2151_CR7","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","volume":"301","author":"PR Kamstrup","year":"2009","unstructured":"Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG (2009) Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301:2331\u20132339","journal-title":"JAMA"},{"key":"2151_CR8","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1253\/circj.CJ-11-0365","volume":"75","author":"H Ikenaga","year":"2011","unstructured":"Ikenaga H, Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Miura F, Nakama Y, Dai K, Otani T, Ejiri K, Oda N, Nakamura M, Miki T (2011) Usefulness of Lipoprotein(a) for predicting progression of non-culprit coronary lesions after acute myocardial infarction. Circ J 75:2847\u20132852","journal-title":"Circ J"},{"key":"2151_CR9","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1373\/clinchem.2007.088013","volume":"53","author":"B Dieplinger","year":"2007","unstructured":"Dieplinger B, Lingenhel A, Baumgartner N, Poelz W, Dieplinger H, Haltmayer M, Kronenberg F, Mueller T (2007) Increased serum lipoprotein(a) concentrations and low molecular weight phenotypes of apolipoprotein(a) are associated with symptomatic peripheral arterial disease. Clin Chem 53:1298\u20131305","journal-title":"Clin Chem"},{"key":"2151_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/cvr\/cvu107","volume":"103","author":"A Laschkolnig","year":"2014","unstructured":"Laschkolnig A, Kollerits B, Lamina C, Meisinger C, Rantner B, Stadler M, Peters A, Koenig W, St\u00f6ckl A, D\u00e4hnhardt D, B\u00f6ger CA, Kr\u00e4mer BK, Fraedrich G, Strauch K, Kronenberg F (2014) Lipoprotein(a) concentrations, apolipoprotein(a) phenotypes, and peripheral arterial disease in three independent cohorts. Cardiovasc Res 103:28\u201336","journal-title":"Cardiovasc Res"},{"key":"2151_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S1078-5884(97)80220-1","volume":"14","author":"SW Cheng","year":"1997","unstructured":"Cheng SW, Ting AC, Wong J (1997) Lipoprotein(a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. Eur J Vasc Endovas Surg 14:17\u201323","journal-title":"Eur J Vasc Endovas Surg"},{"key":"2151_CR12","doi-asserted-by":"publisher","first-page":"555","DOI":"10.5551\/jat.56457","volume":"28","author":"K Yanaka","year":"2021","unstructured":"Yanaka K, Akahori H, Imanaka T, Miki K, Yoshihara N, Kimura T, Tanaka T, Asakura M, Ishihara M (2021) Relationship between lipoprotein(a) and angiographic severity of femoropopliteal lesions. J Atheroscler Thromb 28:555\u2013561","journal-title":"J Atheroscler Thromb"},{"key":"2151_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12928-019-00602-z","volume":"35","author":"O Kawarada","year":"2020","unstructured":"Kawarada O, Hozawa K, Zen K, Huang HL, Kim SH, Choi D, Park K, Kato K, Kato T, Tsubakimoto Y, Ichihashi S, Fujimura N, Higashimori A, Sato T, Yan BP, Pang SY, Wongwanit C, Leong YP, Chua B, George RK, Chen IC, Lee JK, Hsu CH, Pua U, Iwata Y, Miki K, Okada K, Obara H (2020) Peak systolic velocity ratio derived from quantitative vessel analysis for restenosis after femoropopliteal intervention: a multidisciplinary review from endovascular Asia. Cardiovasc Interv Ther 35:52\u201361","journal-title":"Cardiovasc Interv Ther"},{"key":"2151_CR14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s12928-020-00669-z","volume":"35","author":"M Sawano","year":"2020","unstructured":"Sawano M, Yamaji K, Kohsaka S, Inohara T, Numasawa Y, Ando H, Iida O, Shinke T, Ishii H, Amano T (2020) Contemporary use and trends in percutaneous coronary intervention in Japan: an outline of the J-PCI registry. Cardiovasc Interv Ther 35:218\u2013226","journal-title":"Cardiovasc Interv Ther"},{"key":"2151_CR15","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","volume":"45","author":"L Norgren","year":"2007","unstructured":"Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, TASC II Working Group (2007) Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 45:S5-67","journal-title":"J Vasc Surg"},{"key":"2151_CR16","doi-asserted-by":"publisher","first-page":"E212","DOI":"10.1002\/ccd.25387","volume":"83","author":"KJ Rocha-Singh","year":"2014","unstructured":"Rocha-Singh KJ, Zeller T, Jaff MR (2014) Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv 83:E212\u2013E220","journal-title":"Catheter Cardiovasc Interv"},{"key":"2151_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.atherosclerosis.2018.07.001","volume":"276","author":"JF Sanchez Mu\u00f1oz-Torrero","year":"2018","unstructured":"Sanchez Mu\u00f1oz-Torrero JF, Rico-Mart\u00edn S, \u00c1lvarez LR, Aguilar E, Alcal\u00e1 JN, Monreal M, Investigators FRENA (2018) Lipoprotein(a) levels and outcomes in stable outpatients with symptomatic artery disease. Atherosclerosis 276:10\u201314","journal-title":"Atherosclerosis"},{"key":"2151_CR18","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015355","volume":"9","author":"J Golledge","year":"2020","unstructured":"Golledge J, Rowbotham S, Velu R, Quigley F, Jenkins J, Bourke M, Bourke B, Thanigaimani S, Chan DC, Watts GF (2020) Association of serum lipoprotein(a) with the requirement for a peripheral artery operation and the incidence of major adverse cardiovascular events in people with peripheral artery disease. J Am Heart Assoc 9:e015355","journal-title":"J Am Heart Assoc"},{"key":"2151_CR19","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/1526602817728068","volume":"24","author":"K Hishikari","year":"2017","unstructured":"Hishikari K, Hikita H, Nakamura S, Nakagama S, Mizusawa M, Yamamoto T, Doi J, Utsugi Y, Sudo Y, Kimura S, Ashikaga T, Takahashi A, Isobe M (2017) Usefulness of lipoprotein(a) for predicting clinical outcomes after endovascular therapy for aortoiliac atherosclerotic lesions. J Endovasc Ther. 24:793\u2013799","journal-title":"J Endovasc Ther."},{"key":"2151_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1583\/09-2733.1","volume":"16","author":"F Giovanetti","year":"2009","unstructured":"Giovanetti F, Gargiulo M, Laghi L, D\u2019Addato S, Maioli F, Muccini N, Borghi C, Stella A (2009) Lipoprotein(a) and other serum lipid subfractions influencing primary patency after infrainguinal percutaneous transluminal angioplasty percutaneous transluminal angioplasty. J Endovasc Ther 16:389\u2013396","journal-title":"J Endovasc Ther"},{"key":"2151_CR21","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner \u017d, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT, ESC Scientific Document Group (2016) 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37:2999\u20133058","journal-title":"Eur Heart J"},{"key":"2151_CR22","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J (2019) 2018AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM \/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol a report of the American college of cardiology\/American heart association task force on clinical practice guidelines. Circulation 139:e1082\u2013e1143","journal-title":"Circulation"},{"key":"2151_CR23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jvs.2006.12.054","volume":"45","author":"Heart Protection Study Collaborative Group","year":"2007","unstructured":"Heart Protection Study Collaborative Group (2007) Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 45:645\u2013654","journal-title":"J Vasc Surg"},{"key":"2151_CR24","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.jacc.2013.09.073","volume":"63","author":"GG Westin","year":"2014","unstructured":"Westin GG, Armstrong EJ, Bang H, Yeo KK, Anderson D, Dawson DL, Pevec WC, Amsterdam EA, Laird JR (2014) Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol 63:682\u2013690","journal-title":"J Am Coll Cardiol"},{"key":"2151_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00380-020-01696-9","volume":"36","author":"T Shimada","year":"2021","unstructured":"Shimada T, Osakada K, Okabe K, Shima Y, Eguchi H, Habara S, Tada T, Taguchi Y, Ikuta A, Takamatsu M, Murai R, Miura K, Ohya M, Amano H, Kubo S, Tanaka H, Maruo T, Fuku Y, Katoh H, Goto T, Kadota K (2021) Impact of high-dose statin on cardiovascular outcomes in real-world patients with ST-elevation acute myocardial infarction. Heart Vessels 36:297\u2013307","journal-title":"Heart Vessels"},{"key":"2151_CR26","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","volume":"69","author":"S Tsimikas","year":"2017","unstructured":"Tsimikas S (2017) A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol 69:692\u2013711","journal-title":"J Am Coll Cardiol"},{"key":"2151_CR27","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ, ODYSSEY LONG TERM Investigators (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372:1489\u20131499","journal-title":"N Engl J Med"},{"key":"2151_CR28","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372:1500\u20131509","journal-title":"N Engl J Med"},{"key":"2151_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","volume":"75","author":"VA Bittner","year":"2020","unstructured":"Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Moriarty PM, Moryusef A, Pordy R, Roe MT, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG, ODYSSEY OUTCOMES Committees and Investigators (2020) Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol 75:133\u2013144","journal-title":"J Am Coll Cardiol"},{"key":"2151_CR30","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O'Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, \u010ce\u0161ka R, Ezhov MV, Jukema JW, Jensen HK, Tokg\u00f6zo\u011flu SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR, Sabatine MS (2019) Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation 139:1483\u20131492","journal-title":"Circulation"},{"key":"2151_CR31","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","volume":"137","author":"MP Bonaca","year":"2018","unstructured":"Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS (2018) Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the fourier trial (further cardiovascular outcomes research with pcsk9 inhibition in subjects with elevated risk). Circulation 137:338\u2013350","journal-title":"Circulation"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-022-02151-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00380-022-02151-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-022-02151-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T03:08:36Z","timestamp":1672974516000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00380-022-02151-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["2151"],"URL":"https:\/\/doi.org\/10.1007\/s00380-022-02151-7","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"type":"print","value":"0910-8327"},{"type":"electronic","value":"1615-2573"}],"subject":[],"published":{"date-parts":[[2022,7,29]]},"assertion":[{"value":"23 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}